Eisai Purchases Land for Production of Synthetic Vitamin E in the U.S.
June 6, 1996 -- Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced today that Eisai U.S.A., Inc., an Eisai affiliate, has acquired approximately 60 acres of land for the establishment of a synthetic Vitamin E production facility in Pasadena, Texas.
Eisai will build the production facility in the Bayport Industrial Area in Pasadena, Texas. The facility's production scale is estimated to be 1,500 tons annually, including potential exports to Europe and Latin America. The facility is expected to employ approximately 40 when it reaches full commercial operations. Eisai plans to invest about $35 million in the project.
Construction of the facility is due to begin in the fall of 1996. The plant is scheduled to be operational in early 1998.
Since its establishment in 1981, Eisai U.S.A., Inc. has marketed bulk chemicals, Vitamin E, and Automatic Ampoule Inspection Machines (AIM), which were developed in Japan by Eisai Co., Ltd. Eisai U.S.A., Inc. will now expand its operations to include the production of synthetic Vitamin E in Texas.
Localization of R&D, production and marketing in the company's globalization process is a high policy priority for Eisai. Eisai's decision to establish a Vitamin E production facility in the U.S. stems from this policy. With the facility's completion, Eisai will have Vitamin E production centers in the U.S. and Japan, ensuring a stable supply for its customers worldwide.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of over $2.9 billion in fiscal year 1994 with approximately 14 percent of sales spent for research and development.